Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B. Daly, Mary A. Dwyer, Catherine Klein et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 1.1k
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Mary B. Daly, Susan Darlow, Robert Pilarski et al.|Journal of the National Comprehensive Cancer Network|2020Cited by 507
Intrathecal delivery of protein therapeutics to the brain: A critical reassessmentPericles Calias, Patricia Dickson, William A. Banks et al.|Pharmacology & Therapeutics|2014Cited by 179
Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS IEmil Kakkis, Merry Passage, Michael F. McEntee et al.|Molecular Genetics and Metabolism|2004Cited by 168
Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluidPatricia Dickson, Emil Kakkis, Michael F. McEntee et al.|Molecular Genetics and Metabolism|2007Cited by 162